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Historically, multiple sclerosis (MS) has been viewed as being primarily driven by T cells.
However, the effective use of anti-CD20 treatment now also reveals an important role for
B cells in MS patients. The results from this treatment put forward T-cell activation rather
than antibody production by B cells as a driving force behind MS. The main question of
how their interaction provokes both B and T cells to infiltrate the CNS and cause local
pathology remains to be answered. In this review, we highlight key pathogenic events
involving B and T cells that most likely contribute to the pathogenesis of MS. These
include (1) peripheral escape of B cells from T cell-mediated control, (2) interaction of
pathogenic B and T cells in secondary lymph nodes, and (3) reactivation of B and T cells
accumulating in the CNS. We will focus on the functional programs of CNS-infiltrating
lymphocyte subsets in MS patients and discuss how these are defined by mechanisms
such as antigen presentation, co-stimulation and cytokine production in the periphery.
Furthermore, the potential impact of genetic variants and viral triggers on candidate
subsets will be debated in the context of MS.
Keywords: Th1/Th17, T-bet+ B cells, CD8+ T cells, Epstein-Barr virus, genetic risk, transmigration, germinal
center, IFN-γ
INTRODUCTION
In multiple sclerosis (MS) patients, pathogenic lymphocytes are triggered in the periphery to
infiltrate the central nervous system (CNS) and cause local inflammation and demyelination. Anti-
CD20 therapy has recently been approved as a novel treatment modality for MS (1–3). Although
this underscores the fact that B cells play a key role in MS, the exact triggers, subsets and effector
mechanisms contributing to the disease course are incompletely understood. The impact of this
therapy on the antigen-presenting rather than the antibody-producing function of B cells in MS
indicates that their interaction with T cells is an important driver of the pathogenesis (1, 4).
Alterations in cytokine production, co-stimulation and antigen presentation most likely contribute
to the development of pathogenic B and T cells that are prone to enter the CNS (4, 5). Such
mechanisms might be influenced by the interplay between genetic and environmental risk factors
(6). The major HLA-DRB1∗1501 locus accounts for 30% of the overall risk (6) and has been shown
to promote B cell-mediated induction of brain-infiltrating T helper (Th) cells in MS patients (4).
Besides for HLA-DRB1∗1501, other genetic risk variants that have been identified in the past
decades also appear to potentiate B and Th cell activation, a feature that is shared amongst several
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autoimmune disorders (7). Furthermore, infectious triggers such
as the Epstein-Barr virus (EBV) alter their function and reactivity
in MS (5, 6, 8, 9). The current view is that transmigration of
lymphocyte subsets into the CNS signifies relapsing disease, while
compartmentalized CNS inflammation, as seen during disease
progression, seems to be driven by tissue-resident populations
(10, 11). Since there is a clear association of relapse occurrence
and radiological disease activity early in MS with the severity of
disability progression later in MS (12), it is crucial to understand
what motivates these cells to invade the CNS and why these cells
instigate local pathology in MS patients.
In this review, we will discuss which and how brain-infiltrating
lymphocyte subsets can contribute to MS pathogenesis. These
pathogenic events are characterized by: (1) peripheral escape
of pathogenic B cells from T cell-mediated control, (2) mutual
activation of pathogenic B and T cells within peripheral germinal
centers, and (3) re-activation of infiltrating B and T cells
within the CNS. We will use current knowledge to consider
the extent to which genetic and viral triggers may drive these
pathogenic events in MS.
IMPAIRED T CELL-MEDIATED CONTROL
OF PATHOGENIC B CELLS IN MS
B and T cells closely interact in secondary lymphoid organs
to generate an optimal immune response against invading
pathogens. Within follicles, B cells recognize antigens via the
highly specific B-cell receptor (BCR), resulting in internalization,
processing and presentation to T cells. This mechanism is
unique and tightly coordinated involving five consecutive and
interdependent steps: (1) B-cell receptor signaling, (2) actin
remodeling, (3) endosomal formation and transport, (4) HLA
class II synthesis and trafficking to specialized late endosomes
(i.e., MIICs), and (5) antigen processing and loading onto HLA
class II molecules for presentation to CD4+ Th cells (13, 14).
Through their interaction with Th cells, germinal center (GC)-
dependent and -independent memory B cells are formed, a
process that is governed by the strength of the HLA/peptide
signal (15). GC B cells respond to interleukin (IL)-21-producing
follicular Th (Tfh) cells to develop into class-switched (IgG+)
subsets or antibody-producing plasmablasts/plasma cells (15, 16).
Memory B cells, in return, specifically trigger Th effector subsets
that help CD8+ cytotoxic T cells (CTLs) to kill the infected
cell (17). In MS, this crosstalk between B and T cells is likely
disturbed, eventually causing pathogenic instead of protective
immunity. This may already start during selection of naive
autoreactive B cells in the periphery.
Normally, after removal of the majority of B-cell clones
expressing polyreactive antibodies in the bone marrow (central
tolerance), surviving autoreactive B cells are kept in check by
peripheral tolerance checkpoints (18). In contrast to most other
autoimmune diseases, only peripheral and not central B-cell
tolerance checkpoints are defective in MS, which coincides with
increased frequencies of naive polyreactive populations in the
blood (18–21). Although the exact cause is currently unknown,
the escape of pathogenic B cells from peripheral control may be
related to (1) chronic T-cell stimulation and (2) T cell-intrinsic
defects (see Figure 1).
Epstein-Barr virus is one of the most thoroughly investigated
pathogens regarding T-cell responses in MS. Many theories
have been proposed how EBV can influence MS pathogenesis
(9). One hypothesis is that, due to the chronic nature of this
infection, continuous antigen presentation by B cells leads to
functionally impaired, so-called “exhausted” T cells (8, 22). This,
together with the impact of HLA and other risk alleles (23),
may result in inappropriate T cell-mediated control of EBV-
infected (pathogenic) B cells. Consistent with this, peripheral
CD8+ CTLs show decreased responses to EBV and not to
cytomegalovirus antigens during the MS course (8). EBV
antigens can also induce IL-10-producing CD4+ T regulatory
cells (Tregs) capable of suppressing effector T-cell responses to
recall antigens (24), as seen for other persistent viral infections
such as lymphocytic choriomeningitis virus (25, 26). However,
forkhead box P3 (FOXP3+) Tregs have also been described
to control infections (27), suggesting that additional T cell-
intrinsic defects are involved. For example, Treg populations
that are enriched in MS patients produce increased levels of
interferon gamma (IFN-γ), express reduced levels of FOXP3
and have defective suppressive activity in vitro (28). This is not
only accompanied with less suppression of effector T cells (29,
30), but possibly also with impaired removal of pathogenic B
cells, as described for other autoimmune diseases (18, 31, 32).
The direct impact of Tregs on B cells in MS patients is still
unknown. Treg function may be altered by variation in IL2RA
and IL7RA, two known MS risk loci (33, 34). FOXP3 correlates
with IL-2 receptor (IL-2R) as well as IL-7 receptor (IL-7R)
expression in Tregs (35). It can thus be expected that IL2RA
and IL7RA (33, 34), but also BACH2 (36) variants impair Treg
development in MS. This may even influence FOXP3- and IL-2R-
expressing CD8+ T cells, which can suppress pro-inflammatory
CD4+ Th cells (37) and are reduced in the blood during MS
relapses (38–40).
THE GERMINAL CENTER AS A
POWERHOUSE OF PATHOGENIC B- AND
TH-CELL INTERACTION IN MS
Th Cells as Inducers of Pathogenic
Memory B Cells
After their escape from peripheral tolerance checkpoints, naive B
cells likely interact with Th cells in GCs to eventually develop into
memory populations potentially capable of infiltrating the MS
brain (Figure 1). Little is known about how peripheral effector
Th cells mediate the development of such pathogenic B cells
in MS patients. In GCs of autoimmune mice, autoreactive B
cells are triggered by Tfh cells producing high levels of IFN-γ
(16). IFN-γ induces the expression of the T-box transcription
factor T-bet, which upregulates CXC chemokine receptor 3
(CXCR3), elicits IgG class switching and enhanced antiviral
responsiveness of murine B cells (41–43). Recently, we found that
B cells from MS patients preferentially develop into CXCR3+
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FIGURE 1 | Model of the key pathogenic events involving human B- and T-cell subsets driving MS disease activity. In MS patients, B- and T-cells interact in the
periphery and central nervous system (CNS) to contribute to disease pathogenesis. In this model, we put forward three important meeting points of pathogenic B
and T cells that drive the disease course of MS. In secondary lymphoid organs, B-cell tolerance defects in MS patients allow EBV-infected B cells to escape from
suppression by CD8+ and T regulatory (Treg) cells (1). Subsequently, these activated B cells enter germinal centers (GCs) and interact with follicular Th cells to
further differentiate into pathogenic memory B cells. Under the influence of IFN-γ and IL-21, B cells develop into T-bet-expressing memory cells, which in turn
activate Th effector cells such as Th17.1 (2). These subsets are prone for infiltrating the CNS of MS patients by distinct expression of chemokine receptors (CXCR3,
CCR6), adhesion molecules (VLA-4) as well as pro-inflammatory cytokines. (3) Within the CNS, IFN-γ-, and GM-CSF-producing T cells and T-bet+ memory B cells
probably come into contact in follicle-like structures, resulting in clonal expansion inflammation and demyelination. T-bet+ memory B cells further differentiate into
plasmablasts/plasma cells to secrete high numbers of potentially harmful antibodies (oligoclonal bands).
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populations that transmigrate into the CNS (44). The IFN-γ
receptor (IFNGR) and downstream molecule signal transducer
and activator of transcription (STAT)1 in B cells are major
determinants of autoimmune GC formation in mice (45, 46).
After ligation of the IFNGR, STAT1 is phosphorylated, dimerizes
and translocates into the nucleus to induce genes involved in
GC responses, such as T-bet and B-cell lymphoma 6 (BCL-
6) (16, 47). Although IFN-γ-stimulated B cells of MS patients
show enhanced pro-inflammatory capacity (44, 48), it is unclear
whether alterations in the IFN-γ signaling pathway contribute
to the development of T-bet+ B cells infiltrating the CNS.
Interestingly, a missense SNP in IFNGR2 has been found in MS,
which may alter their development (49, 50). Another target gene
of the IFN-γ pathway is IFI30, which encodes for the IFN-γ-
inducible lysosomal thiol reductase (GILT) and is considered one
of the causal risk variants in MS (7). GILT is a critical regulator
of antigen processing for presentation by HLA class II molecules
(51–53). Together, these findings point to T-bet-expressing B cells
as potent antigen-presenting cells that are highly susceptible to
triggering by IFN-γ-producing Th effector subsets in MS (44,
54) (Figure 2).
Epstein-Barr virus may be an additional player in the
formation of T-bet-expressing B cells. In mice, persistent viral
infections sustain the development of these types of B cells,
in which T-bet enhances their ability to recognize viral and
self-antigens (41, 55). EBV is hypothesized to persist latently
in pathogenic B cells and mimic T-cell help for further
differentiation in GCs (5, 22, 56, 57). During acute infection,
EBV uses a series of latency programs that drive B cells
toward a GC response in an antigen-independent manner.
Latent membrane protein (LMP)2A and LMP1 resemble signals
coming from the BCR and CD40 receptor (56, 57). In addition
to their regulation of GC responses independently of T-cell
help (58), recent evidence implicates that LMP2A and LMP1
can synergize with BCR and CD40 signaling as well (59).
Interestingly, downstream molecules of the BCR (e.g., Syk, CBL-
B) and CD40 receptor (e.g., TRAF3) are genetic risk factors for
MS (23, 60), therefore potentially cooperating with these latent
proteins to enhance pathogenic B-cell development (Figure 2).
This is supported by the binding of LMP2A to Syk in B cells
and their escape from deletion in GCs of transgenic mice (61).
Alternatively, pathogenic B cells can be induced via pathogen-
associated TLR9, which binds to unmethylated CpG DNA and
further integrate with BCR, CD40, and cytokine signals (62–65).
Moreover, pathogenic B-cell responses in systemic autoimmune
diseases such as systemic lupus erythematosus are enhanced
after IFN-γ and virus-mediated induction of the T-bet (45,
55, 64, 65). In MS patients, TLR9 ligation is also a major
trigger of pro-inflammatory B cells (48) and crucial for the
differentiation of T-bet-expressing IgG1+ B cells during IFN-
γ- and CD40-dependent GC-like cultures in vitro. Thus, under
influence of specific genetic factors, EBV might join forces
with IFN-γ-producing Th cells to stimulate pathogenic (T-
bet+) GC B cells both in a direct (via infection and persistence
in pathogenic subsets) and indirect (via TLR7/9) fashion in
MS (Figure 2).
B Cells as Inducers of Pathogenic
Memory Th Cells
Synchronously, within peripheral GCs, T-bet-expressing memory
B cells are ideal candidates to trigger IFN-γ-producing, CNS-
infiltrating Th cells in MS (Figure 1). In both mice and humans,
T-bet promotes the antigen-presenting cell function of B cells.
This may be related to the impact of EBV infection on B
cell-intrinsic processing and presentation of antigens such as
myelin oligodendrocyte glycoprotein (MOG) (5). The potent
antigen-presenting cell function of B cells in MS patients is
further reflected by the effective use of anti-CD20 therapy. This
therapy does not affect antibody serum levels, but significantly
reduces pro-inflammatory Th-cell responses in MS, both ex vivo
and in vivo (1). CD20 was found to be enriched on IFN-
γ-inducible T-bet-expressing IgG+ B cells in MS blood (44),
pointing to this pathogenic subset as an important therapeutic
target. Furthermore, genetic changes in HLA class II molecules,
as well as costimulatory molecules [e.g., CD80 (66, 67) and
CD86 (68)], may additionally enhance Th cell activation by such
memory B cells (Figure 2). HLA class II expression on murine
B cells was reported to be indispensable for EAE disease onset
(69, 70). The in silico evidence that autoimmunity-associated
HLA class II molecules have an altered peptide-binding groove
(71, 72), together with the potential role of several minor risk
variants in the HLA class II pathway [e.g., CIITA, CLEC16A, IFI30
(Figure 2)], insinuates that antigens are differently processed
and presented by B cells (4, 5). This is supported by the
increased ability of memory B cells to trigger CNS-infiltrating Th
cells in MS patients carrying HLA-DRB1∗1501 (4). These CNS-
infiltrating T cells induced by B cells showed features of both Th1
and Th17, therefore representing highly pathogenic subsets. Such
subsets are characterized by master transcription factors T-bet
and RORγt (73, 74), of which the latter is involved in the co-
expression of IL-17 and GM-CSF in mice but not in humans
(75, 76). GM-CSF is an emerging pro-inflammatory cytokine
produced by Th cells in MS (33, 75, 77). Our group recently
revealed that a Th subset producing high levels of IFN-γ and
GM-CSF, but low levels of IL-17, termed Th17.1, plays a key role
in driving early disease activity in MS patients (78). Proportions
of Th17.1 cells were reduced in the blood and highly enriched
in the CSF of rapid-onset MS patients. In addition, Th17.1 cells
and not classical Th1 and Th17 cells accumulated in the blood
of MS patients who clinically responded to natalizumab (anti-
VLA-4 mAb). The increased pathogenicity of Th17.1 is further
exemplified by their high levels of multidrug resistance, anti-
apoptotic and cytotoxicity-associated genes ABCB1 (MDR1),
FCMR (TOSO) and GZMB (granzyme B), respectively (78–81).
Th17.1 cells also show pronounced expression of the IL-23
receptor (IL-23R) (78), which is essential for maintaining the
pathogenicity of Th17 cells during CNS autoimmunity (82). IL-23
signals through the IL-23R and IL-12 receptor beta chain (IL-
12Rβ1), resulting in JAK2-mediated STAT3 and TYK2-mediated
STAT4 phosphorylation, and thereby inducing RORγt and T-bet,
respectively (83). IL-12RB1, TYK2, STAT3, and STAT4 are known
genetic risk variants and thus may directly induce Th effector
cells in MS (Figure 2). In addition to its potential effect on Tregs
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FIGURE 2 | Potential contribution of EBV and genetic risk factors to pathogenic B- and Th-cell development in MS patients. IFN-γ is a key player in autoreactive
B- and Th-cell interaction and autoimmune germinal center (GC) formation in mice. In MS, we propose that EBV infection together with specific genetic risk variants
promote the IFN-γ-mediated interplay between B and T cells within GCs. EBV directly infects naive B cells and mimic GC responses. EBV DNA can also bind to
TLR7/9, and together with IFN-γ, induces T-bet+ memory B cells. Their interplay may be additionally stimulated by both B cell-intrinsic (IFN-γ sensitivity: IFNGR2;
B cell receptor-antigen uptake: CBLB, SYK, CLEC16A; HLA class II pathway: CLEC16A, CIITA, IFI30; co-stimulation: CD80, CD86) and Th cell-intrinsic (surface
receptors: IL2RA, IL7RA, IL12RB1; downstream molecules: TYK2, STAT3, STAT4) genetic risk variants. IL12R/IL-23R complexes trigger JAK2/STAT3-dependent
RORγt and TYK2/STAT4-dependent T-bet expression in Th effector cells.
(see above), MS-associated risk variant IL-2RA enhances GM-
CSF production by human Th effector cells (33). To confirm the
influence of these and other risk loci (84) on the induction of
pathogenic Th cells such as Th17.1 in MS, functional studies need
to be performed in the near future.
The increased pathogenicity of Th effector cells may
additionally be skewed by IL-6-producing B cells (85, 86),
which have been shown to trigger autoimmune GC formation
and EAE in mice (87, 88). Blocking of IL-6 prevents the
development of myelin-specific Th1 and Th17 cells in EAE
(89). The IL-6-mediated resistance of pathogenic Th cells to
Treg mediated suppression in MS (90, 91) further links to the
abundant expression of anti-apoptotic gene FCMR in Th17.1 (78,
92). Intriguingly, B cell-derived GM-CSF can be an additional
cytokine driving pathogenic Th cells in MS patients by inducing
pro-inflammatory myeloid cells (93). Although the causal MS
autoantigen is still unknown, previous work implies that B
cell-mediated presentation of EBV antigens at least contributes
to pathogenic Th-cell induction (5, 94). As mentioned above,
antiviral CD8+ CTLs can become exhausted during persistent
viral infections. Normally, this mechanism is compensated by the
presence of cytotoxic CD4+ Th cells, which keep these types of
infections under control (95). Such Th populations have been
associated with MS progression (96) and are also formed after
EBV infection, producing high levels of IFN-γ, IL-2, granzyme
B, and perforin (97, 98). Similarly, EBV- and myelin-reactive
Th cells from MS patients produce high levels of IFN-γ and
IL-2 (6) and strongly respond to memory B cells presenting
myelin peptides (99). These studies indicate that the involvement
of EBV-infected B cells, especially those expressing T-bet (see
section “Th Cells as Inducers of Pathogenic Memory B Cells”),
in activating Th effector cells with cytotoxic potential (78, 100,
101) deserves further attention in MS.
REACTIVATION OF CNS-INFILTRATING
B AND T CELLS IN MS
Mechanisms of Infiltration
Under normal physiological conditions, the CNS has been
considered an immune privileged environment and consists of a
limited number of lymphocytes that cross the blood brain barrier
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(BBB) (102). However, the revelation of meningeal lymphatic
structures emphasized the cross-talk between CNS and peripheral
lymphocytes in secondary lymphoid organs (103). The choroid
plexus has been identified as the main entry of memory cells
into the CNS, which is in the case of T cells mostly mediated
by CCR6 (104, 105). The normal human CSF, as is acquired
from the arachnoid space by lumbar spinal taps, contains more
CD4+ Th cells compared to CD8+ T cells with central memory
characteristics (106–108). The arachnoid space is a continuum
with the perivascular space surrounding penetrating arterial and
venous structures into the parenchyma (109). Within the brain
parenchyma, more CD8+ T cells than CD4+ Th cells are found,
however, their numbers remain low and can be found virtually
restricted to the perivascular space (11, 110). These T cells
display a phenotype mostly associated with non-circulating tissue
resident memory T cells. The perivenular perivascular space
has been argued to be the common drainage site of antigens
mobilized with the glymphatics flow (111). The exact relationship
between memory T cells in the subarachnoid and perivascular
space has been poorly identified in terms of replenishment and
clonal association.
The BBB is dysfunctional during the early phase of MS,
resulting in or is due to local recruitment of pathogenic T
and B cells (112). Differential expression of pro-inflammatory
cytokines, chemokine receptors and integrins by infiltrating
lymphocytes have been argued to mediate disruption of the
BBB in MS (104, 113). Myelin-reactive CCR6+ and not CCR6−
memory Th cells from MS patients not only produce high levels
of IL-17, but also IFN-γ and GM-CSF (80). Previous studies
mainly focused on the migration of IL-17-producing CCR6+ Th
cells through the choroid plexus in EAE and in vitro human
brain endothelial cell layers in MS brain tissues (104, 114).
In our recent study, we subdivided these CCR6+ memory Th
cells into distinct Th17 subsets and found that especially IFN-γ
producing Th17.1 (CCR6+CXCR3+CCR4−) cells were capable
of infiltrating the CNS, both in ex vivo autopsied brain tissues
and in in vitro transmigration assays (78). The fact that Th17.1
cells have cytotoxic potential and strongly co-express IFN-γ with
GM-CSF (78) suggests that these cells are involved in disrupting
the permeability of the BBB in MS (115, 116). The impact of
CXCR3 on their transmigration capacity is likely the result of
binding to the chemokine ligand CXCL10, which is produced
by brain endothelial cells and is abundant in the CSF of MS
patients (117, 118). Similar observations were made for CXCR3
(T-bet)+ B cells (44). CCR6 is also highly expressed on memory
B-cell precursors within the Th cell-containing light zone of GCs
(119), and on IFN-γ-producing CD8+ T cells infiltrating the MS
brain (120). This implies that both populations are susceptible
to enter the CNS of MS patients. In addition to chemokine
receptors and pro-inflammatory cytokines, adhesion molecules
such as activated leukocyte cell adhesion molecule (ALCAM)
enhance transmigration of pathogenic B and T cell subsets (115,
121, 122). Furthermore, CXCR3 is co-expressed with integrin
α4β1 (VLA-4), which allows both B- and T-cell populations to
bind to vascular cell adhesion protein 1 (VCAM-1) on brain
endothelial cells (123). This is supported by the reducing effects
of VLA-4 inhibition on B- and Th17-cell infiltration into the
CNS and disease susceptibility in EAE (124). Natalizumab, a
monoclonal antibody against VLA-4, is used as an effective
second-line treatment for MS (125). Discontinuation of this
treatment often results in severe MS rebound effects (126).
Hence, the peripheral entrapment of populations like Th17.1 and
T-bet+ B cells in natalizumab-treated patients (44, 78) probably
underlies the massive influx of blood cells causing these effects.
The same is true for EBV-reactivated B cells, which are enriched
in lesions from MS patients after natalizumab withdrawal (127).
A previous gene network approach using several GWAS datasets
further highlights the relevance of adhesion molecules on the BBB
endothelium for the crossing of T and B cells (128), especially
those affected by IFN-γ (115).
Local Organization and Impact
Both B and T cells accumulate in active white matter lesions of the
MS brain (10, 129). In diagnostic biopsy studies, T cell-dominated
inflammation is a characteristic of all lesion-types observed (130).
Also in post-mortem MS lesions, white matter MS lesions with
active demyelination associate with an increase in T cell numbers
(10, 129). Although CD4+ Th cells are in general outnumbered
by CD8+ CTLs in brain lesions as investigated in autopsy studies
(10), their role as triggers of local pathology should not be
overlooked in MS. This is consistent with the enrichment of
CD4+ Th cells in white matter lesions with active demyelination
(10). An abundant number of CD4+ Th cells were also visible in
pre-active lesion sites, suggesting an involvement of these cells
in the early stages of lesion formation (131). Additionally, it was
demonstrated that in contrast to CD8+ CTLs, brain-associated
CD4+ Th-cell clonotypes are reduced in MS blood, indicating
specific recruitment (as described above) or, alternatively, clonal
expansion in the CNS (132). Furthermore, dominant Th-
cell clones were undetectable following reconstitution after
autologous hematopoietic stem cell transplantation in MS
patients, which was not seen for CD8+ T cells (133). Interestingly,
T-cell clones are shared between CNS compartments within a
patient, including CSF and anatomically separated brain lesions
(132, 134–137). This suggests that brain-infiltrating T cells bear
similar reactivity against local (auto)antigens.
In subsets of MS autopsy cases with acute and relapsing
remitting MS, B cells can also be found predominantly in
the perivascular space in association with active white matter
lesions (10). The role of these perivascular B cells, including
T-bet+ B cells (44), could be to re-activate (infiltrating) pro-
inflammatory CD4+ and CD8+ T cells to cause MS pathology
(Figure 1). Identical B-cell clones have been found in different
CNS compartments of MS patients, including the meninges
(138, 139). Within the meninges, B- and T cell-rich follicle-like
structures have been found that localize next to cortical lesions,
presumably mediating progressive loss of neurological function
in MS (140, 141). Interestingly, MS brain-infiltrating lymphocytes
express and respond to IL-21 (142), the cytokine that drives
follicular T- and B-cell responses. Additionally, IFN-γ triggering
of B cells promotes ectopic follicle formation in autoimmune
mice (16, 45), suggesting that the structures observed in the MS
CNS are induced by B cells interacting with IFN-γ-producing
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T cells. However, the role of IL-17 in this process should not be
ruled out, as shown in EAE (143).
Besides mediating migration and organization of pathogenic
lymphocytes in the MS brain, cytokines are likely relevant effector
molecules. IFN-γ production by Th cells also associates with
the presence of demyelinating lesions in the CNS (144–146).
IFN-γ, and possibly also GM-CSF, can activate microglia or
infiltrated macrophages to cause damage to oligodendrocytes
(93, 147, 148). As for B cells, increased production of TNF-
α, IL-6, and GM-CSF has been found (48, 87) and we have
recently shown that during Tfh-like cultures, IFN-γ drives IgG-
producing plasmablasts in MS (44). One could speculate that
after their re-activation by IFN-γ-producing Th cells within
the meningeal follicles, T-bet+ memory B cells rapidly develop
into antibody-producing plasmablasts/plasma cells (Figure 1).
IFN-γ-induced GC formation promotes the generation of
autoantibodies in lupus mice (16, 45). The targeting of B cells
and not plasmablasts/plasma cells by clinically effective anti-
CD20 therapies in MS, as well as the abundance of oligoclonal
bands in MS CSF, at least support the local differentiation of
B cells into antibody-secreting cells (48, 149). We argue that
IgG secreted by local T-bet-expressing plasmablasts/plasma cells
are highly reactive in the MS brain (43, 44, 55), although the
(auto)antigen specificity and pathogenicity of such antibodies
remain unclear in MS, as well as their contribution as effector
molecules to MS pathology.
Several antigenic targets have been proposed to contribute
to MS pathology. Next to myelin, which is one of the most
intensively studied antigens (150), also EBV antigens are
considered as major candidates. EBNA-1 specific IgG antibodies
are predictive for early disease activity (151) and are present
in CSF from MS patients (152, 153). Some studies imply that
reactivated B cells in ectopic meningeal follicles (154, 155) cross-
present EBV peptides to activate myelin- and EBNA-1 specific Th
cells (6, 156, 157). Whether EBV is detected in the brain or solely
recognized in the periphery and how this contributes to local
pathology is still a matter of intense debate in the field (127, 158–
162). In addition to myelin (150) and EBV (6), other antigenic
targets of locally produced IgG and infiltrating T cells have been
suggested, such as sperm-associated antigen 16 [SPAG16 (163)],
neurofilament light, RAS guanyl-releasing protein 2 [RASGRP2
(4)], αB-crystallin and GDP-l-fucose synthase (135).
CONCLUDING REMARKS
In this review, we have discussed potential triggers and
mechanisms through which interacting B and T cells drive the
pathogenesis of MS. In our presented model, peripheral B cells
escape from tolerance checkpoints as the result of impaired
control by chronically exhausted or genetically altered regulatory
T cells. Subsequently, B cells interact with IFN-γ-producing
effector Th cells in germinal centers of lymphoid organs to create
a feedforward loop, after which highly pathogenic subsets break
through blood-CNS barriers and, together with infiltrating CD8+
CTLs are locally reactivated to cause MS pathology. Although
definite proof is still lacking, these pathogenic events are likely
mediated by an interplay between persistent infections such
as EBV and genetic risk variants. Together, these factors may
alter the selection, differentiation and pathogenic features of
B- and T-cell subsets. In our view, more in-depth insights into
how infections and genetic burden define the CNS-infiltrating
potential and antigen specificity of such subsets should be the
next step to take in the near future. The development of small
molecule therapeutics against subsets driving the disease course
would be an effective way of generating clinically relevant benefits
without harmful effects in MS patients.
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